Edition:
United States

Obseva SA (OBSV.OQ)

OBSV.OQ on NASDAQ Stock Exchange Global Select Market

12.98USD
15 Aug 2018
Change (% chg)

-- (--)
Prev Close
$12.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
23,456
52-wk High
$20.31
52-wk Low
$6.20

Select another date:

Fri, Jul 6 2018

ObsEva plans Swiss listing; trading debut on July 13

ZURICH ObsEva , a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors.

UPDATE 1-ObsEva plans Swiss listing; trading debut on July 13

ZURICH, July 6 ObsEva, a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors.

ObsEva plans Swiss listing; trading debut on July 13

ZURICH, July 6 ObsEva, a Switzerland-based drug development company, said on Friday it is keen on a secondary listing on the SIX Swiss Exchange in Zurich, with a trading debut on July 13, as the firm seeks to gain more notice from European investors.

BRIEF-Obseva Reports Q1 Loss Per Share $0.54

* OBSEVA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-ObsEva Reports Q4 Loss Per Share $0.48

* OBSEVA REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Obseva Q4 Loss Per Share $0.48

* OBSEVA REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Obseva Reports Positive Topline Results From Implant2 Phase 3 Clinical Trial Of Nolasiban In IVF

* OBSEVA SA REPORTS POSITIVE TOPLINE RESULTS FROM IMPLANT2 PHASE 3 CLINICAL TRIAL OF NOLASIBAN IN IVF

Select another date: